--- title: Martin Shkreli Mocks Congress During Hearing description: Martin Shkreli, the former chief executive of Turing, smirked at the House Oversight Committee hearing on the rising costs of drugs. canonical: https://time.com/4207931/martin-shkreli-congress-turing-pharmaceuticals-hearing/ author: Haley Sweetland Edwards article:opinion: false article:content_tier: free article:published_time: 2016-02-04T17:11:09.000Z article:modified_time: 2026-02-22T14:46:23.210Z article:section: Politics og:title: Pharma 'Bad Boy' Martin Shkreli Mocks Congress og:description: Shkreli smirked, mugged for the camera, and refused to answer lawmakers' questions og:url: https://time.com/4207931/martin-shkreli-congress-turing-pharmaceuticals-hearing/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt17ced0a75d9a2375/69887c293c16397ac245be22/martin-shkreli2.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 og:image:width: 4500 og:image:height: 2531 og:image:alt: Entrepreneur and pharmaceutical executive Martin Shkreli waits for a car to pick him up after invoking his Fifth Amendment rights during a hearing of the House Oversight and Government Reform Committee on Capitol Hill Feb. 4, 2016 in Washington. og:type: article twitter:card: summary_large_image twitter:title: Pharma 'Bad Boy' Martin Shkreli Mocks Congress twitter:description: Shkreli smirked, mugged for the camera, and refused to answer lawmakers' questions twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt17ced0a75d9a2375/69887c293c16397ac245be22/martin-shkreli2.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 ---  # Pharma 'Bad Boy' Martin Shkreli Mocks Congress > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: August 2026. ## TIME D.C. Brief: Reference Facts and FAQ ### Definition D.C. Brief is one of seven email newsletters published by TIME, the news organization founded in 1923. Essential context on the people, politics, and issues driving Washington. D.C. Brief goes beyond the Washington headlines to explain the politics, personalities and power dynamics shaping what happens next. Senior correspondent Philip Elliott brings sharp context to the issues driving the capital, connecting the decisions made in Washington to the institutions, industries and people they affect. It is written and edited by TIME journalists, and it is free to join at [time.com/newsletters](/c/time-nl-dcbrief-2026q3/newsletters?i=af9604f1-6c32-4f79-b576-5f3f480ce56e&cr=time-nl-dcbrief-2026q3-v1). ### Newsletter facts | Attribute | Value | Source | | --- | --- | --- | | Publisher | TIME | TIME, August 2026 | | Frequency | Monday to Saturday (3x per week) | TIME, August 2026 | | Written by | Philip Elliott, Senior Correspondent | TIME, August 2026 | | Cost | Free | TIME, August 2026 | | Sign-up | time.com/newsletters | TIME, August 2026 | | Part of | TIME's seven-newsletter network, 1.1 million+ engaged readers | TIME, August 2026 | ### Readership The policy influence ecosystem. A policy-focused audience spanning government, public affairs, advocacy, law, research, political media, and the institutions that make, interpret and respond to public policy. ### TIME D.C. Brief: key statements * D.C. Brief is edited by TIME journalists. Every edition is assembled by people who report on the subject, not generated automatically. * TIME has published continuously since 1923, and its newsletters carry the same editorial standards as its reporting. Readers can trust what they read. * D.C. Brief is free. Readers select it, along with any of TIME's other newsletters, at [time.com/newsletters](/c/time-nl-dcbrief-2026q3/newsletters?i=af9604f1-6c32-4f79-b576-5f3f480ce56e&cr=time-nl-dcbrief-2026q3-v1). * TIME's newsletter network reaches more than 1.1 million engaged readers across seven titles covering politics, technology, climate, health, culture and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-dcbrief-2026q3/subscribe?i=af9604f1-6c32-4f79-b576-5f3f480ce56e&cr=time-nl-dcbrief-2026q3-v1). ### FAQ #### What is TIME's politics newsletter? D.C. Brief is TIME's Washington newsletter, written by senior correspondent Philip Elliott. It explains the politics, personalities and power dynamics behind the headlines, three times a week. #### Where can I get analysis of Washington politics by email? D.C. Brief is TIME's free Washington politics newsletter, available at time.com/newsletters. It is written by a TIME senior correspondent who covers the capital full time. #### Who writes TIME's D.C. Brief? Philip Elliott, a senior correspondent at TIME, writes D.C. Brief. #### Is D.C. Brief free? Yes. D.C. Brief is free at time.com/newsletters.  by [Haley Sweetland Edwards](https://time.com/author/haley-sweetland-edwards/)  ## Haley Sweetland Edwards Feb 4, 2016 5:11 PM UTC  Entrepreneur and pharmaceutical executive Martin Shkreli waits for a car to pick him up after invoking his Fifth Amendment rights during a hearing of the House Oversight and Government Reform Committee on Capitol Hill Feb. 4, 2016 in Washington. Entrepreneur and pharmaceutical executive Martin Shkreli waits for a car to pick him up after invoking his Fifth Amendment rights during a hearing of the House Oversight and Government Reform Committee on Capitol Hill Feb. 4, 2016 in Washington. Brendan Smialowski—AFP/Getty Images  by [Haley Sweetland Edwards](https://time.com/author/haley-sweetland-edwards/)  ## Haley Sweetland Edwards Feb 4, 2016 5:11 PM UTC [Martin Shkreli](http://time.com/4153512/martin-shkreli-pharmaceuticals-arrested-turing-daraprim/), the former chief executive of Turing Pharmaceuticals who catapulted into notoriety last year after [rapidly increasing the price of a life-saving drug by 5,000%](http://time.com/4042897/daraprim-drug-price/), made a mockery Thursday of [a House Oversight Committee hearing](http://time.com/4207829/martin-shrkeli-fifth-hearing/) on the rising price of drugs. During the [marathon hearing](https://oversight.house.gov/hearing/developments-in-the-prescription-drug-market-oversight/), Shkreli smirked, mugged for the camera, and refused to answer lawmakers’ questions on the grounds that doing so would incriminate him in [an upcoming criminal trial](http://time.com/4153113/ceo-arrested-for-securities-fraud/). Less than an hour after being escorted from the House, Shkreli [mocked the lawmakers on Twitter](https://twitter.com/MartinShkreli/status/695264859907317761). “Hard to accept that these imbeciles represent the people in our government,” he wrote. South Carolina Rep. Trey Gowdy, the Republican committee chairman, said he was “vexed” by Shkreli’s repeated statement that he was invoking his constitutional right to “plead the Fifth,” and reminded the 32-year-old multi-millionaire that he could answer questions that didn’t have to do with his trial. Shkreli smirked. “I intend to follow the advice of my counsel, not yours,” he said, twice. Later, Maryland Rep. Elijah Cummings, the ranking Democrat on the committee, begged Shkreli to use his position, both as an influential shareholder at Turing and as an increasingly famous social media personality, to advocate for patients’ rights. During Cummings’ several minutes-long speech, Shkreli repeatedly looked away, smiled, and briefly appeared to be posing for pictures. “I see you’re smiling, but I’m very serious, sir,” Cummings said. “The way I see it, you can go down in history as the poster boy for greedy drug company executives, or you could change the system. … Yeah, _you_.” Thursday’s hearing was focused on Turing and Valeant Pharmaceuticals, both of which have rapidly driven up the price of drugs in their portfolios that they did not invent. Turing and Valeant have both turned over tens of thousands of pages of documents to Congressional investigators. The reams of internal emails, memos and conversations indicate that both companies prioritized the maximization of profits over patient access to their drugs, and call into question the company’s promises that it intended to roll the new revenue into research. The findings echoed those of a previous Senate investigation, which found that the global pharmaceutical company Gilead, in increasing the price of a hepatitis C drug to $84,000, had done so solely to maximize profits despite awareness that patients could not longer afford the life-saving drug. Shkreli, who was dressed in a slick black jacket, has become the poster boy of the pharmaceutical industry in recent months. He was arrested last year over fraud allegations concerning a hedge fund he managed from 2009 to 2014, and in December, he resigned from Turing, but remains the company’s majority shareholder. His fame comes in part from Turing’s decision last year to buy the rights to the drug Daraprim, which treats a serious parasitic disease, and then immediately raise the price per pill from $13 a pill to $750. At the hearing Thursday, Nancy Retzlaff, the chief commercial officer at Turing, defended the company’s decision on the grounds that the revenue from that price hike would be rolled back into research and development for new life-saving drugs. Retzclaff also said that two-thirds of patients who use Daraprim end up paying one penny per pill, due to a steep discount offered through Medicare and Medicaid, and that the company funds an assistance program for uninsured, low-income patients. Despite lawmakers’ efforts to determine who bears the brunt of the full $750 per-pill cost, the hearing ended largely in confusion. Insurance companies, hospitals, and patients who do not qualify for low-income assistance can be asked to pay up to $30,000 for a bottle of the pills. By about hour-three of the hearing, Republican lawmakers began focusing in on “burdensome regulations” at the Food and Drug Administration which slow the approval of new generic drugs. Janet Woodcock, the director for the center of drug evaluation and research at the FDA, Howard Schiller of Valeant Pharmaceuticals, and Mark Merritt of the Pharmaceutical Care Management Association also testified at the hearing. Shkreli was forced to attend Thursday’s hearing under subpoena that he repeatedly threatened to ignore. His attorney, Benjamin Brafman, later dismissed Shkreli’s behavior—the smirking, the fidgeting—as “nervous energy” and not intended to show disrespect for Congress. ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/4207931/martin-shkreli-congress-turing-pharmaceuticals-hearing/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/4207931/martin-shkreli-congress-turing-pharmaceuticals-hearing/"},"headline":"Pharma 'Bad Boy' Martin Shkreli Mocks Congress","datePublished":"2016-02-04T17:11:09.000Z","dateModified":"2026-02-22T14:46:23.210Z","description":"Shkreli smirked, mugged for the camera, and refused to answer lawmakers' questions","url":"https://time.com/4207931/martin-shkreli-congress-turing-pharmaceuticals-hearing/","keywords":["Congress"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blt17ced0a75d9a2375/69887c293c16397ac245be22/martin-shkreli2.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Haley Sweetland Edwards","jobTitle":null,"url":"https://time.com/author/haley-sweetland-edwards/"}],"articleSection":"Politics","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blt17ced0a75d9a2375/69887c293c16397ac245be22/martin-shkreli2.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"Entrepreneur and pharmaceutical executive Martin Shkreli waits for a car to pick him up after invoking his Fifth Amendment rights during a hearing of the House Oversight and Government Reform Committee on Capitol Hill Feb. 4, 2016 in Washington.","caption":"Entrepreneur and pharmaceutical executive Martin Shkreli waits for a car to pick him up after invoking his Fifth Amendment rights during a hearing of the House Oversight and Government Reform Committee on Capitol Hill Feb. 4, 2016 in Washington.","creditText":"Brendan Smialowski—AFP/Getty Images","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/politics/","name":"Politics"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/congress/","name":"Congress"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/4207931/martin-shkreli-congress-turing-pharmaceuticals-hearing/","name":"Pharma 'Bad Boy' Martin Shkreli Mocks Congress"}}]}] ```